TLS Beta Pte. Ltd. 4
4 · Guardant Health, Inc. · Filed Oct 11, 2018
Insider Transaction Report
Form 4
TLS Beta Pte. Ltd.
10% Owner
Transactions
- Conversion
COMMON STOCK
2018-10-09+596,012→ 596,012 total(indirect: By TLS Beta Pte. Ltd.) - Conversion
SERIES E PREFERRED STOCK
2018-10-09−596,012→ 0 total(indirect: By TLS Beta Pte. Ltd.)→ COMMON STOCK (596,012 underlying) - Conversion
SERIES D PREFERRED STOCK
2018-10-09−1,016,995→ 0 total(indirect: By TLS Beta Pte. Ltd.)→ COMMON STOCK (1,016,995 underlying) - Conversion
COMMON STOCK
2018-10-09+1,016,995→ 1,016,995 total(indirect: By TLS Beta Pte. Ltd.)
Footnotes (2)
- [F1]The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.
- [F2]The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.